Show simple item record

dc.contributor.authorLawler, Men_US
dc.contributor.authorAlsina, Den_US
dc.contributor.authorAdams, RAen_US
dc.contributor.authorAnderson, ASen_US
dc.contributor.authorBrown, Gen_US
dc.contributor.authorFearnhead, NSen_US
dc.contributor.authorFenwick, SWen_US
dc.contributor.authorHalloran, SPen_US
dc.contributor.authorHochhauser, Den_US
dc.contributor.authorHull, MAen_US
dc.contributor.authorKoelzer, VHen_US
dc.contributor.authorMcNair, AGKen_US
dc.contributor.authorMonahan, KJen_US
dc.contributor.authorNäthke, Ien_US
dc.contributor.authorNorton, Cen_US
dc.contributor.authorNovelli, MRen_US
dc.contributor.authorSteele, RJCen_US
dc.contributor.authorThomas, ALen_US
dc.contributor.authorWilde, LMen_US
dc.contributor.authorWilson, RHen_US
dc.contributor.authorTomlinson, Ien_US
dc.contributor.authorBowel Cancer UK Critical Research Gaps in Colorectal Cancer Initiativeen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2018-02-13T16:32:05Z
dc.date.accessioned2019-02-27T11:50:26Z
dc.date.issued2018-01en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/29233930en_US
dc.identifiergutjnl-2017-315333en_US
dc.identifier.citationGut, 2018, 67 (1), pp. 179 - 193en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3105
dc.identifier.eissn1468-3288en_US
dc.identifier.doi10.1136/gutjnl-2017-315333en_US
dc.description.abstractOBJECTIVE: Colorectal cancer (CRC) leads to significant morbidity/mortality worldwide. Defining critical research gaps (RG), their prioritisation and resolution, could improve patient outcomes. DESIGN: RG analysis was conducted by a multidisciplinary panel of patients, clinicians and researchers (n=71). Eight working groups (WG) were constituted: discovery science; risk; prevention; early diagnosis and screening; pathology; curative treatment; stage IV disease; and living with and beyond CRC. A series of discussions led to development of draft papers by each WG, which were evaluated by a 20-strong patient panel. A final list of RGs and research recommendations (RR) was endorsed by all participants. RESULTS: Fifteen critical RGs are summarised below: RG1: Lack of realistic models that recapitulate tumour/tumour micro/macroenvironment; RG2: Insufficient evidence on precise contributions of genetic/environmental/lifestyle factors to CRC risk; RG3: Pressing need for prevention trials; RG4: Lack of integration of different prevention approaches; RG5: Lack of optimal strategies for CRC screening; RG6: Lack of effective triage systems for invasive investigations; RG7: Imprecise pathological assessment of CRC; RG8: Lack of qualified personnel in genomics, data sciences and digital pathology; RG9: Inadequate assessment/communication of risk, benefit and uncertainty of treatment choices; RG10: Need for novel technologies/interventions to improve curative outcomes; RG11: Lack of approaches that recognise molecular interplay between metastasising tumours and their microenvironment; RG12: Lack of reliable biomarkers to guide stage IV treatment; RG13: Need to increase understanding of health related quality of life (HRQOL) and promote residual symptom resolution; RG14: Lack of coordination of CRC research/funding; RG15: Lack of effective communication between relevant stakeholders. CONCLUSION: Prioritising research activity and funding could have a significant impact on reducing CRC disease burden over the next 5 years.en_US
dc.format.extent179 - 193en_US
dc.languageengen_US
dc.language.isoengen_US
dc.relation.replaceshttps://repository.icr.ac.uk/handle/internal/1052
dc.relation.replacesinternal/1052
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectcolorectal canceren_US
dc.subjectBiomedical Researchen_US
dc.subjectColorectal Neoplasmsen_US
dc.subjectEarly Detection of Canceren_US
dc.subjectEvidence-Based Medicineen_US
dc.subjectGene-Environment Interactionen_US
dc.subjectGenetic Predisposition to Diseaseen_US
dc.subjectHumansen_US
dc.subjectRisk Factorsen_US
dc.titleCritical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-10-25en_US
rioxxterms.versionofrecord10.1136/gutjnl-2017-315333en_US
rioxxterms.licenseref.startdate2018-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfGuten_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Molecular & Population Genetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular & Population Genetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Translational Oncogenomics
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume67en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMolecular & Population Geneticsen_US
icr.researchteamTranslational Oncogenomicsen_US
dc.contributor.icrauthorMarsden,en_US
dc.contributor.icrauthorHoulston, Richarden_US
dc.contributor.icrauthorGerlinger, Marcoen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/